SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership in the Czech market through the Almeda Company, a Prague-based firm specializing in medical device sales in the region for almost two decades.
Michel Vaudry, SpectraScience's Director of International Sales commented that "the Czech Republic is attractive on many fronts as an entry point into the European market for our WavSTAT System, both for its aging population and its established $1.2 billion medical device market. In addition, the Czech Republic has one of the highest incidences of colorectal cancer in the world. We are exploring additions to our export sales team in other European countries such as Italy, Germany and France."
Almeda's Director Ales Zavorka stated that "the WavSTAT System fills a
significant gap in our product offering to the Czech market which has a
particularly high incidence of colon cancer. Other drivers for the product
in the market are its ease of use and performance, both of which are
extremely appealing to the physician community."
Key Benefits to the WavSTAT Optical Biopsy System
-- Leaves polyps on site if they are not pre-cancerous
-- Ability for physician to perform physical biopsy at exactly same site
as optical biopsy
-- Aids physician during colon cancer surgery
-- Complementary to NBI and Smart Pill
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements involve risks and uncertainties that may cause
SpectraScience's actual results to differ materially from results discussed
in forward-looking statements. Readers are urged to carefully review and
consider the various disclosu
|SOURCE SpectraScience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved